JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) ROCE % : 0.00% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is JW (Cayman) Therapeutics Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. JW (Cayman) Therapeutics Co's annualized ROCE % for the quarter that ended in Dec. 2023 was 0.00%.

JW (Cayman) Therapeutics Co ROCE % Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co ROCE % Chart

JW (Cayman) Therapeutics Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-190.47

-82.10

-21.97

-29.58

-34.17

JW (Cayman) Therapeutics Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial						-27.17	-29.43	-31.02	-30.90	-

JW (Cayman) Therapeutics Co ROCE % Calculation

JW (Cayman) Therapeutics Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-105.821	/	( ( (400.383 - 44.585)	+	(300.565 - 37.039) )	/ 2 )
	=	-105.821	/	( (355.798	+	263.526)	/ 2 )
	=	-105.821	/	309.662
	=	-34.17 %

JW (Cayman) Therapeutics Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	0	/	( ( (370.371 - 48.671)	+	(300.565 - 37.039) )	/ 2 )
	=	0	/	( ( 321.7	+	263.526 )	/ 2 )
	=	0	/	292.613
	=	0.00 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

JW (Cayman) Therapeutics Co (OTCPK:JWCTF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

JW (Cayman) Therapeutics Co ROCE % Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (OTCPK:JWCTF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

02126:Hong Kong

Address

No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN

Website

https://www.jwtherapeutics.com

JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Headlines

No Headlines